VaxInnate
Advancing the future of healthcare with innovative vaccines for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus since 2002.
Advancing the future of healthcare with innovative vaccines for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus since 2002.
VaxInnate is a biotechnology company that has been advancing the future of healthcare since 2002. The company is dedicated to creating innovative vaccines for various illnesses, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. Based in Cranbury, New Jersey, VaxInnate focuses on healthcare, health diagnostics, and biotechnology. The company received a significant $3.25M Venture Round investment on 28 September 2015.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $3.25M | - | 28 Sep 2015 | |
| Venture Round | $6.00M | 1 |
|
02 Oct 2014 |
| Grant | $2.10M | - | 28 Jan 2014 | |
| Grant | $2.20M | 1 | National Institute of Allergy and Infectious Diseases | 04 Apr 2013 |
| Debt Financing | $24.81M | - | 24 Feb 2012 |
No recent news or press coverage available for VaxInnate.
We care about your data, and we'd love to use cookies make your experience better.